CBPO [China Biologic Products] SC 13D: (Original Filing)
[]
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
[SCHEDULE 13G/A (Amendment No. 3)* Renren Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.001 per share (Title of Class of Securities) 759892300** (CUSIP Number) June 19, 2020 (Date of event which requires filing of this statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) (Page 1]
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[This Form 6-K consists of: 1. 2. Announcement 1 (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 00386) Resignation of Director The board of directors (the " Board ") of China Petroleum & Chemical Corporation (" Sinopec Corp. " or the]
[This Form 6-K consists of: 1. 2. Announcement 1 (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 00386) Resignation of Director The board of directors (the " Board ") of China Petroleum & Chemical Corporation (" Sinopec Corp. " or the]